SCHEMBL1013784

SCHEMBL1013784

Cc1nc(N2CCN(C)CC2)ncc1C(=O)NC1CCCCCC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
NR3C1 P04150 2/20 0.50
CNR2 P34972 1/20 0.50
MAPT P10636 4/20 0.48
HSD11B1 P28845 1/20 0.47
KMT2A Q03164 2/20 0.47
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 2/20 0.47
HPGD P15428 1/20 0.47
HSD17B10 Q99714 1/20 0.47
LMNA P02545 1/20 0.46
BMPR1B O00238 1/20 0.46
BMPR1A P36894 1/20 0.46
TGFBR1 P36897 1/20 0.46
ACVRL1 P37023 1/20 0.46
ACVR1 Q04771 1/20 0.46
TSHR P16473 1/20 0.45
MEN1 O00255 1/20 0.45
CYP1A2 P05177 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1014719 1.00 POLB (0.53) POLBSMN1; SMN2NR3C1CNR2MAPT
SCHEMBL1017870 0.92 POLB (0.64) POLBSMN1; SMN2NR3C1MAPTHSD11B1
SCHEMBL1014776 0.92 POLB (0.64) POLBSMN1; SMN2NR3C1MAPTHSD11B1
SCHEMBL1014028 0.90 POLB (0.61) POLBSMN1; SMN2NR3C1MAPTHSD11B1
SCHEMBL1014750 0.88 POLB (0.50) POLBSMN1; SMN2NR3C1CNR2MAPT
SCHEMBL1014425 0.87 HSD11B1 (0.61) POLBSMN1; SMN2NR3C1CNR2MAPT
SCHEMBL1015182 0.87 HSD11B1 (0.61) POLBSMN1; SMN2NR3C1CNR2MAPT
SCHEMBL1015708 0.87 POLB (0.52) POLBSMN1; SMN2NR3C1MAPTHSD11B1
SCHEMBL1014757 0.86 PTPN11 (0.50) POLBSMN1; SMN2NR3C1MAPTHSD11B1
SCHEMBL1014624 0.86 HSD11B1 (0.62) POLBSMN1; SMN2CNR2MAPTHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2271629-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 AstraZeneca AB (SE) 2011-01-12 EP disclosed
WO-2009130496-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 ASTRAZENECA AB (SE) 2009-10-29 WO disclosed
US-20090264401-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 ASTRAZENECA AB (SE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264401-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 CYP2S1, HSD11B1, HSD3B1 POLB 2006/4885SMN1; SMN2 2203/4885NR3C1 971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.